Becton, Dickinson and Company (BD) has completed the acquisition of US medical technology firm C. R. Bard for about $24bn.
In April 2017, BD first signed an agreement to acquire Bard, which develops, produces and sells medical technologies in the fields of vascular, urology, oncology and surgical specialties.
The acquisition will allow Bard to enhance its presence in fast-growing clinical areas, in addition to expanding operations in non-US markets.
The combined firm will provide end-to-end medication management solutions across the care continuum, enabling to offer ore product solutions for healthcare associated infections (HAIs).
BD will now offer comprehensive and clinically relevant products for surgical site infections (SSIs) and catheter-related blood stream infections (CRBSIs).
BD chairman and CEO Vince Forlenza said: “These companies each have a legacy of more than 100 years of advancing the world of health and supporting those on the frontlines of health care.
“We look forward to continuing to lead the industry through innovation and partnerships that bring more valuable solutions to our customers and their patients.”
In October 2016, BD and Apax Partners have established a new global respiratory solutions company, Vyaire Medical.
Vyaire Medical includes BD’s Respiratory Solutions business lines, comprising of ventilation, respiratory diagnostics, vital signs and AirLife products.
With around 5,000 associates across the globe, the new firm includes locations in Yorba Linda an Palm Springs of California, as well as Plymouth of Minnesota in the US.
In May 2015, BD acquired CareFusion for around $12.2bn, which manufactures Alaris infusion pumps and IV sets, MaxPlus and MaxZero IV connectors and sets, Pyxis automated dispensing and patient identification systems.
Image:BD has acquired US medical technology firm Bard. Photo: courtesy of adamr / FreeDigitalPhotos.net.